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Key Points
• Prior malignancy nega-
tively impacts survival in
patients with MM and
.1 prior malignancy
reduces survival even
further.
• A prior malignancy di-
agnosis increases the
risk of developing a
second malignancy in
patients with MM.
In the present study, we aimed to evaluate 2 hypotheses. First, we hypothesize that prior
malignancy is a proxy for genetic susceptibility that could be a risk factor for subsequent
malignancy development in multiple myeloma (MM) patients. Second, we hypothesize that
survival after MM is inﬂuenced by a prior malignancy. All patients diagnosed with MM
from 1 January 1973 to 31 December 2010 were identiﬁed from the Swedish Cancer Register.
Cox regression model was used to calculate hazard ratios (HRs) and 95% conﬁdence
intervals (CIs) where prior malignancy was compared in MM patients who developed a
subsequent malignancy and MM patients who did not. In another Cox regression model,
survivalwas compared inMMpatientswithandwithout apriormalignancydiagnosis. A total
of 19 791 patients were diagnosed with MM. Patients with a prior malignancy diagnosis had
a signiﬁcantly increased risk of developing a subsequent malignancy compared with MM
patients without (HR 1.42, 95% CI 1.23-1.65, P , .001). MM patients with a prior malignancy
diagnosis had a signiﬁcant 1.21-fold increased risk of death (95% CI 1.115-1.26, P , .001)
compared with MM patients without. MM patients with 2 or more prior malignancy
diagnoses had a 1.34-fold increased risk of death (95% CI 1.19-1.52, P , .001). In this large
population-based study, we report that prior malignancy increases the risk of subsequent
malignancy development in MM patients. Furthermore, we found that prior malignancy
negatively impacts survival and that .1 prior malignancy reduces survival even further.
Introduction
With improved survival in patients with multiple myeloma (MM), awareness of second malignancies has
increased during recent years.1-5We have previously shown in a large population-based study that the risk of
developing any second malignancy is 26% higher in MM patients compared with the general population;
most importantly, they had an 11-fold increased risk of developing acute myeloid leukemia and
myelodysplastic syndromes (MDS) and a twofold increased risk of developing nonmelanoma skin cancer.6
Other studies have found MM patients to have an increased risk of developing certain types of second
cancers, such as melanoma, nervous system tumors, and kidney and urinary tract tumors, although
mechanisms and risk factors are not well understood.7-10 Suggested risk factors for second malignancies
include treatment-, disease-, environmental-, behavioral-, and host-related factors.4,11-13 Host-related factors
include both genetic and nongenetic; reported nongenetic factors include age, male sex, and obesity.1,8,14
Genetic factors implicated in the development of second malignancies include polymorphisms in genes
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encoding drug-metabolizing enzymes andDNA repair pathways.15,16 In
addition, inherited genetic susceptibility for developing MM has been
supported by genome-wide association studies that have identified
single-nucleotide polymorphisms localized to several genomic regions
that are robustly associated with MM risk.17 Furthermore, familial
studies on MM patients and their first-, second-, and third-degree
relatives have shown a significant excess of cases of prostate cancer
and melanoma in all types of relatives.18 This might suggest that the
genetic cause of MM overlaps with the causes of other cancers.18-23
Information regarding prior malignancies and their impact on MM
patients is limited. For instance, patients with prior malignancies are
often excluded from clinical trials,24,25 thus making it difficult to
generalize the current literature to this group. In addition, previously
published results on the effect of prior malignancies have been
conflicting.1,26 In the present study, we aimed to evaluate 2
hypotheses. First, we hypothesize that prior malignancy is a proxy for
inherent genetic susceptibility that could be a risk factor for subsequent
malignancy development in MM patients. Second, we hypothesize that
survival after MM is influenced by a prior malignancy.
Methods
Central registry
All residents in Sweden have equal access to health care under a
largely decentralized, taxpayer-funded system. All malignancy di-
agnoses are reported to the centralized nationwide Swedish Cancer
Registry, which was established in 1958.27 The diagnostic accuracy
and overall completeness of the Swedish Cancer Registry is high
(.95%).28,29 Pathologists and physicians in Sweden are obliged by
law to report each malignancy diagnosis to this register. Within the
register, information on sex, date of birth, date of malignancy
diagnosis, malignancy type, and date of death is registered.
Patient cohort
All patients diagnosed with MM from 1 January 1973 to 31
December 2010 were identified from the Swedish Cancer Registry.
Information was gathered on sex, date of birth, date of MM diagnosis,
and date of death. All cancer diagnoses prior to and after MM diagnosis
were identified through cross-linkage within the Swedish Cancer
Registry, and the type and date of the cancer were documented. Prior
and subsequent malignancies were classified according to the
International Classification of Disease-7 into the following subgroups:
(1) breast cancer; (2) bone and cartilage; (3) ear, nose, and throat; (4)
endocrine; (5) female reproductive; (6) gastrointestinal; (7) hematolog-
ical; (8) kidney and urinary tract; (9) male reproductive; (10) melanoma;
(11) nervous system; (12) respiratory tract; (13) soft tissue and
mediastinal; and (14) unspecified tumors.
Approval was obtained from the Regional Ethical Review Board in
Stockholm for this study. Informed consent was waived because we
had no contact with study patients.
Data analysis
Risk factor analysis, assessing the effect of prior
malignancies on the development of second malignancies
in MM. The exposure was the binary categorical variable of a first
malignancy diagnosis before MM diagnosis, and the outcome was the
binary categorical variable of a primary malignancy diagnosis after MM
diagnosis. Demographic characteristics were compared between
groups using frequency measures and percentages as well as median
values. A Cox regression model was used to calculate hazard ratios
(HRs) and 95% confidence intervals (CIs) where prior malignancy was
compared between MM patients who developed a subsequent
malignancy and those who did not, adjusted for age at MM diagnosis,
date of MM diagnosis, and sex. Two-sided P , .05 was considered
statistically significant. All MM patients in the study were censored either
at date of death, at the time of first subsequent malignancy diagnosis, or
at the end of study (31 December 2013), whichever occurred first. All
malignancy diagnoses from autopsies were excluded. Malignancies in
the same patient with exactly the same International Classification of
Disease diagnosis code were both included if they were registered with
more than a 5-year interval (recurrent disease). Time from first prior
malignancy diagnosis toMMdiagnosis (T1)was compared betweenMM
patients who developed a subsequent primary malignancy and those
who did not with Mann-Whitney-Wilcox test. Time fromMM diagnosis to
subsequent malignancy diagnosis (T2) was compared between those
who had a prior malignancy diagnosis and those who did not with the
Mood’s median test.
A subgroup analysis was conducted with the same Cox regression
model as described above to assess the risk of developing a
specific subsequent malignancy subtype in MM patients with a prior
malignancy diagnosis compared with those without.
Survival analysis. Survival was estimated from the date of
the MM diagnosis until death, emigration, or end of study
(31 December 2013), whichever occurred first. The Kaplan-Meier
method was used to estimate survival in MM patients with and
without a prior malignancy diagnosis. A Cox proportional hazard
model was used to calculate HRs and 95% CIs. Two-sided P, .05
was considered statistically significant. A dose-dependent relation-
ship, analyzing the effect of increasing number of malignancies on
survival, was estimated using the same method, adjusting for age at
MM diagnosis, date of MM diagnosis, and sex.
All statistical analyses were done with R version 3.1.1. (R foundation
for Statistical Computing, Vienna, Austria).
Results
A total of 19 791 patients were diagnosed with MM in Sweden from
1 January 1973 to 31 December 2010. Of these, 2469 (12.5%)
patients had 1 or more prior malignancy diagnoses at the time of
MM diagnosis, and 17 322 (87.5%) patients had no prior history of
malignancy. A total of 216 (8.8%) MM patients with a prior
malignancy developed subsequent malignancies. The number of
MM patients without a prior malignancy that developed a sub-
sequent malignancy was 1257 (7.3%). Baseline patient character-
istics of these groups are compared in Table 1. Types of both prior
and subsequent malignancies are seen in Figure 1.
MM patients with a prior malignancy diagnosis had an increased risk of
developing a subsequent malignancy afterMMdiagnosis comparedwith
MM patients without a prior malignancy (HR 1.42; 95% CI 1.23-1.65,
P , .001) (Table 2). In a subgroup analysis, any prior malignancy in
MM patients was associated with an increased risk of developing
hematological (1.59; 95%CI 1.04-2.42,P5 .032), malignantmelanoma
(HR 2.67; 95% CI 1.43-5.00, P 5 .002), nonmelanoma skin cancer
(HR 1.99; 1.47-2.71, P , .001), and malignancies of the respiratory
tract (HR 3.24; 1.79-5.88, P , .001) (Table 2).
The median time from the first prior malignancy diagnosis to MM
diagnosis was 7.1 years both in the group that did not develop a
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subsequent malignancy and in the group that did develop a subse-
quent malignancy (P 5 .732). The median time to first subsequent
malignancy diagnosis was 2.3 years (range 0.02-21.5) among patients
who had a prior malignancy diagnosis compared with 3.2 years (range
0.003-37.5) in patients who did not have a prior malignancy diagnosis
(P 5 .003).
MM patients with a prior malignancy diagnosis had a statistically
significant 21% increased risk of death (HR 5 1.21, 95% CI
1.15-1.26, P , .001) compared with MM patients without a prior
malignancy diagnosis (Figure 2). In a dose-response analysis, MM
patients with $2 malignancy diagnoses had a 34% increased risk
of death (HR5 1.34, 95% CI 1.19-1.52, P , .001) compared with
MM patients without a prior malignancy diagnosis (Figure 2).
Discussion
In our large population-based study, we found that prior malignancy
diagnosis increased the risk of developing hematologic malignancies,
melanoma, nonmelanoma skin cancer, and respiratory tract malignan-
cies in patients with MM. In addition, we show that prior malignancy
negatively impacts survival in patients with MM and that .1 prior
malignancy reduces survival even further. We confirmed prior reports
of solid tumors being more common than hematologic malignancies in
MM patients, both prior and subsequent to the MM diagnosis.2,26,30
We found that 12.5% of patients with MM had prior malignancy and
8.1% developed a second malignancy. These results are similar to the
findings of a recent registry analysis on 744MM patients by Engelhardt
et al.1 Although another study by Hasskarl et al reported lower rates,
7% and 3%, respectively,2 we also found that 6.6% of prior
malignancies and 12.5% of subsequent malignancies were hemato-
logical. This rate of subsequent hematological malignancies has been
observed in hematological malignancies other than MM, such as
Hodgkin lymphoma.31 The most frequently diagnosed malignancies
prior to MM were gastrointestinal and female- and male-reproductive
cancers. This is in line with Engelhardt et al’s study,1 although we found
breast cancers to be more common compared with their study.
A prior malignancy diagnosis in MM patients was associated with a
40% increased risk of developing a subsequent malignancy, and
these patients developed their subsequent malignancy almost a
year sooner than those without a history of prior malignancy. There
are limited published data regarding this association, and 2 recent
registry studies reported conflicting results.1,26 The Connect MM
registry study by Rifkin et al comprised 1430 MM patients treated
with lenalidomide and reported that prior invasive malignancies
increased the risk of developing subsequent malignancies.26 In
contrast to this, Engelhardt et al reported in a registry study
including 774 MM patients that prior malignancy did not increase
the risk of a subsequent malignancy.1 These studies have a small
number of patients that developed second malignancies, 49 and 59
patients, respectively. Underlying explanation for our findings, that
a prior malignancy increases the risk of second malignancies in
MM patients, could include genetic susceptibilities,17-22,32-35
immunosuppression,36-38 and therapy-related cancers.12,13,39
We found MM patients with a prior cancer diagnosis to have an
increased risk of developing hematological malignancy, melanoma,
nonmelanoma skin cancer, and respiratory malignancy compared
with MM patients who did not. We have previously shown that both
patients with the precursor condition monoclonal gammopathy of
undetermined significance and MM have an increased risk of
developing nonmelanoma skin cancer, suggesting a possible
biological relationship.6 Increased incidence of melanoma in MM
patients has also been reported,8,40 and it has been shown that
both melanoma and nonmelanoma skin cancers are increased in
other immunocompromised patient groups.36-38 Interestingly, famil-
ial studies on MM patients and their relatives have shown a
significant excess of cancers such as melanoma in these families,
suggesting that in some cases the genetic cause of MM might
overlap with that of melanoma. In addition, studies have found the
same oncogenic mutations in both MM and melanoma.19,32,33,41
We found an association between prior malignancy and the
Table 1. Patient characteristics
MM with prior
malignancies
MM without prior
malignancies
Patients, n (%) 2469 (12.5) 17 322 (87.5)
Age at MM diagnosis, median (range), y 75 (34-98) 71 (19-99)
Male sex, n (%) 1220 (49.4) 9 483 (54.5)
Year of MM diagnosis
by category, n
1973-1980 197 3 188
1981-1990 463 4 657
1991-2000 720 4 644
2001-2010 1089 4 833
Year of MM diagnosis, median
(range)
1999 (1973-2010) 1992 (1973-2010)
Follow-up, median (range), y 2.0 (0.003-29.4) 2.6 (0.003-40.9)
Time to subsequent malignancy, median
(range), y
2.3 (0.02-21.5) 3.2 (0.003-37.5)
Prior malignancy type,
no. of patients (%)
Hematologic 163 (6.6) —
Gastrointestinal 323 (13.1) —
Male reproductive 427 (17.3) —
Female reproductive 401 (16.2) —
Breast 329 (13.3) —
Kidney and urinary tract 186 (7.5) —
Melanoma 125 (5.1) —
Nonmelanoma skin cancer 235 (9.5) —
Respiratory 43 (1.7) —
Ear, nose, and throat 46 (1.8) —
Endocrine 93 (3.8) —
Nervous system 61 (2.4) —
Bone and cartilage 6 (0.2) —
Soft tissue and mediastinal 17 (0.7) —
Unspecified tumors 14 (0.6) —
Number of prior malignancy
diagnoses
1 2158 —
$2 311 —
Patients with subsequent
malignancies, n (%)
216 (8.8) 1 257 (7.3)
—, Not applicable; n, number of patients.
2394 JONSDOTTIR et al 28 NOVEMBER 2017 x VOLUME 1, NUMBER 25
development of respiratory malignancies in MM patients. To our
knowledge, MM patients have not been found to have increased risk
of developing respiratory malignancies; on the contrary, data from
the Surveillance, Epidemiology, and End Results database suggest
reduced incidence in MM patients.40 The most common prior
malignancy diagnosis in MM patients with subsequent respiratory
tract cancer was female reproductive cancer (40%; more
specifically, cervical cancer). The reason for this is unclear. Smoking
is a risk the factor for both cervical cancer and respiratory tract
malignancies,42 although it is not a risk factor for MM. The increased
incidence of hematological malignancies, specifically acute myeloid
leukemia/MDS, is well documented in MM patients,4,6,12,13 where
alkylating agents have been considered to be 1 of the main
contributing factors, although a role for non-treatment-related
factors has also been reported,4-6,8 and the recent discovery of a
genotype associated with the development of MDS in MM22
supports a role for susceptibility genes in this development.
Taken together, a prior cancer diagnosis increased the risk of
second malignancy development in MM patients and might suggest
inherent genetic susceptibility in these patients, although further
research is needed to confirm this.
We found that prior malignancy negatively impacts survival in MM
patients. We showed that this relationship was dose dependent
because patients with 2 or more prior malignancy diagnoses had a
significantly twofold increased risk of death compared with patients
with 1 prior malignancy diagnosis. Interestingly, studies have found
patients with other hematological malignancies, such as chronic
lymphocytic leukemia, to have a reduced survival if they had a prior
history of nonmelanoma skin cancer.43 The pathologic mechanism
behind these findings is unknown, but the authors suggested that
patients with prior history of nonmelanoma skin cancer might have
more aggressive disease. Our results confirm the findings that prior or
synchronous malignancies increased the risk of death in MM patients.1
Reduced survival in MM patients with prior malignancies is likely
multifactorial and could include reduced dose intensity of chemo- and
radiation therapy, detrimental effects of previous chemo-radiation or
surgical treatments on physical condition of patients, or that MM that
develops after another malignancy might be biologically different.
Taken together, the impact of prior malignancies is clinically relevant for
the individual patient and warrants future research and attention.
Our study has several strengths, including a large sample size, long study
period, and application of high-quality population-based data from
Sweden. By using the nationwide register-based design, where data are
gathered prospectively, we were able to account for recall bias and
ensure the generalizability of our results. Underreporting of tumors
should not affect our results to any extent because the overall
completeness of the Swedish Cancer Registry has been reported to
be .95%, although substantial underreporting has been noted for
leukemia.28 In a recent validation study, the diagnostic accuracy
was ;98% for hematopoietic lymphoproliferative malignancies in
Sweden.29
Limitations include the lack of detailed clinical and treatment data
for the patient population in our study, including information on
cause of death, pathological stage of the prior cancers, MM, and
subsequent cancers. In addition, we did not have information on
genetic profiles. A possible bias in cohort selection due to left
censoring cannot be excluded, but we designed the study period to
allow prior malignancies to be recorded, because the Swedish
Cancer Registry started in 1958 and patient enrollment started in
0
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Figure 1. Number of prior and subsequent malignancies
in MM patients according to malignancy types. Group
letters: A, ear, nose, and throat; B, gastrointestinal; C,
respiratory; D, bone and cartilage; E, melanoma; F, non-
melanoma skin cancer; G, soft tissue and mediastinal; H,
breast malignancy; I, female reproductive; J, male reproductive;
K, kidney and urinary tract; L, nervous system; M, endocrine;
N, unspecified tumors; O, hematological; and P, eye tumors.
Table 2. The risk of developing a certain subsequent malignancy
subtype in MM patients with a prior malignancy diagnosis
compared with those without
HR 95% CI P
Overall 1.42 1.23-1.65 <.001
Hematologic (n 5 193) 1.59 1.04-2.42 .032
Gastrointestinal (n 5 318) 1.13 0.81-1.58 .475
Male reproductive (n 5 204) 0.74 0.44-1.26 .276
Female reproductive (n 5 58) 0.71 0.28-1.79 .468
Breast (n 5 83) 1.16 0.61-2.22 .643
Kidney and urinary tract (n 5 105) 1.40 0.80-2.41 .234
Melanoma (n 5 58) 2.67 1.43-5.00 .002
Nonmelanoma skin cancer (n 5 256) 1.99 1.47-2.71 <.001
Respiratory (n 5 64) 3.24 1.79-5.88 <.001
Oral, nasal, and pharyngeal (n 5 18) 1.30 0.29-5.86 .731
Endocrine (n 5 24) 0.78 0.18-3.37 .736
Nervous system (n 5 35) 0.86 0.26-2.87 .808
Bone and cartilage (n 5 5) — — —
Soft tissue and mediastinal (n 5 13) 1.91 0.40-9.03 .415
Unspecified tumors (n 5 39) 1.28 0.49-3.33 .618
Two-sided P , .05 was considered statistically significant, shown in boldface.
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1973, allowing for a 15-year lead time. In addition, we stratified our
data according to decade of MM diagnosis and age category.
Regarding the risk factor analysis, it should be considered that
because survival is significantly reduced in patients with prior
malignancies, this group could possibly have had less time to
develop a subsequent malignancy compared with patients without a
prior malignancy. On the contrary, the patients with prior malignancy
developed their subsequent malignancy significantly earlier than
patients without a prior malignancy. To minimize this effect, we
adjusted for age at MM diagnosis. Because patients could be
diagnosed with a prior and second malignancy 1 day before and
after MM diagnosis, we performed a sensitivity analysis excluding all
patients diagnosed with prior or subsequent malignancy within a
month of the MM diagnosis with no effect to our overall findings
(data not shown). Several of the subtype analyses had a limited
number of patients and should be interpreted with caution.
In this large population-based study, including ;20 000 patients
with MM, we report that prior malignancy increases the risk of
subsequent malignancy development in MM patients. Furthermore,
we found that prior malignancy negatively impacts survival and that
.1 prior malignancy reduces survival even further. The underlying
explanation for our findings could suggest a role for susceptibility
genes in the development of second malignancies; other possible
etiologies include immune dysfunction in these patients or side
effects from treatment. Given the increase of malignancy survivors
in general, our findings are of importance both for the individual
patients and their families and for the treating physician.
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